Strategic Agreement
-
Exchanging a CAR-T therapy for 18% of the shares, the decision-making of Innovent Biologics
All comments are highly welcome!
-
Radionetics Oncology Enters Into Strategic Agreement With Lilly on its proprietary GPCR targeting small molecule radiopharmaceuticals
Warmest congratulations to Eli Lilly and Radionetics Oncology!
